5 most-read payer issues stories: Week of Jan. 30-Feb.3

Aetna’s decision to potentially move its Hartford, Conn., headquarters to Boston struck a chord with Becker’s Hospital Review payer issues readers this week.

Advertisement

The following were among this week’s most-viewed payer issues stories on Becker’s Hospital Review.

1. Aetna considers moving HQ to Boston: 4 things to know
Hartford, Conn.-based Aetna engaged in discussions with the Massachusetts’ governor’s office regarding a potential transfer of its headquarters to Boston.

2. Anthem beats estimates as Q4 adjusted net income jumps 55%
Indianapolis-based Anthem reported an adjusted net income of $473.2 million in the fourth quarter of this year, a year-over-year increase of 54.7 percent from $305.8 million.

3. Questions around ACA replacement put insurers in strategic deadlock
While lawmakers wage efforts to repeal and replace the ACA, health insurers are questioning what a replacement will look like — leaving many with limited strategies, such as sustaining their ACA exchange operations or completely exiting the market.

4. Anthem cites ruling in Aetna antitrust case to strengthen its arguments
Two days after the district court issued its decision to block Aetna’s proposed $37 billion acquisition of Humana over antitrust concerns, Anthem filed four pages of arguments citing excerpts of the judge’s ruling as evidence its planned acquisition of Cigna should proceed.

5. Aetna’s Q4 net profit falls 57%, but still beats forecasts 
Hartford, Conn.-based Aetna saw its net profit drop 57 percent in the fourth quarter of fiscal year 2016 to $139 million, down from $321 million during the same period last year. 

More articles on payer issues:
Anthem, Cigna assessing participation in 2018 ACA exchanges: 4 things to know
Anthem beats Q4 estimates, Cigna’s revenue gets a boost, Capital BlueCross acquires Vibra & more — 9 payer highlights
Study: Consumers purchasing individual plans fair better in post-ACA market

 

Advertisement

Next Up in Payer

Advertisement

Comments are closed.